4-溴-1-甲基-1H-苯并[D][1,2,3]三唑 | 1378259-89-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 4-溴-1-甲基-1H-苯并[D][1,2,3]三唑
• 英文名称: 4-bromo-1-methyl-1H-benzotriazole
• 英文别名: 4-bromo-1-methyl-1H-benzo[d][1,2,3]triazole；4-Bromo-1-methyl-1H-1,2,3-benzotriazole；4-bromo-1-methylbenzotriazole
• CAS: 1378259-89-2
• 化学式: C₇H₆BrN₃
• 分子量: 212.049
• InChiKey: RIFALXBGBJHMER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-溴-1-甲基-1H-苯并[D][1,2,3]三唑 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 1-methyl-5-(1-methyl-3-{[4-(1-methyl-1H-benzotriazol-4-yl)phenoxy]methyl}-1H-pyrazol-4-yl)pyridin-2(1H)-one
  参考文献：
  名称：

  解决在一系列新的联芳基衍生物中观察到的光毒性：发现有效，选择性和口服活性的磷酸二酯酶10A抑制剂ASP9436

  摘要：

  我们合成了几种作为PDE10A抑制剂的联芳基衍生物，以防止2- [4-（{[1-甲基-4-（吡啶-4-基）-1] H-吡唑-3-基]氧基}甲基）苯基]喹啉的光毒性（1）发现联芳基的能量最小构象和共平面构象之间的能量差有助于促进联芳基化合物的光毒性潜力的预测。在3T3 NRU测试中，用N-甲基苯并咪唑取代1的喹啉环增加了这种能量差并防止了光毒性。进一步优化确定了1-甲基-5-（1-甲基-3-{[4-（1-甲基-1 H-苯并咪唑-4-基）苯氧基]甲基} -1 H-吡唑-4-基）吡啶- 2（1小时）-一（38b）。化合物38b显示出对其他PDE的良好选择性，并且在新颖的物体识别测试中，口服施用38b改善了小鼠的视觉识别记忆缺陷，剂量为0.001和0.003mg / kg。因此，ASP9436（倍半磷酸盐的38b）可用于治疗具有低光毒性风险的精神分裂症。

  DOI：

  10.1016/j.bmc.2015.04.052
• 作为产物：
  描述：

  2-溴-6-氟硝基苯 在 盐酸 、 potassium carbonate 、 溶剂黄146 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 33.0h， 生成 4-溴-1-甲基-1H-苯并[D][1,2,3]三唑
  参考文献：
  名称：

  Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information

  摘要：

  Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulators (PAMs) have been implicated as potential pharmacotherapy for psychiatric conditions. Screening our corporate compound deck, we identified a benzotriazole fragment (4) that was rapidly optimized to a potent and metabolically stable early lead (16). The highly lipophilic character of 16, together with its limited solubility, permeability, and high protein binding, however, did not allow reaching of the proof of concept in vivo. Since further attempts on the optimization of druglike properties were unsuccessful, the original hit 4 has been revisited and was optimized following the principles of fragment based drug discovery (FBDD). Lacking structural information on the receptor ligand complex, we implemented a group efficiency (GE) based strategy and identified a new fragment like lead (60) with more balanced profile. Significant improvement achieved on the druglike properties nominated the compound for in vivo proof of concept studies that revealed the chemotype being a promising PAM lead targeting mGluR2 receptors.

  DOI：

  10.1021/acs.jmedchem.8b00161

文献信息

• Nonaqueous Electrolyte and Nonaqueous Secondary Battery
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：US20180062213A1

  公开（公告）日：2018-03-01

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.
• WO2024059559A1
  申请人：——

  公开号：——

  公开（公告）日：——